Orforglipron: Research, Clinical Trials, and UK Availability

What Is Orforglipron?

Orforglipron is a next-generation treatment under development for weight management and type 2 diabetes. Belonging to the GLP-1 receptor agonist family, it shares similarities with injectable treatments like Wegovy® and Mounjaro®, but with one key difference –it’s taken orally.

Currently undergoing advanced clinical trials, Orforglipron offers a tablet-based alternative to weekly injections, with early data showing strong results in both weight reduction and blood sugar regulation.

How Does Orforglipron Work?

Orforglipron mimics the effects of GLP-1, a hormone naturally produced in the gut. It targets receptors that:

●      Suppress appetite

●      Slow gastric emptying

●      Enhance insulin secretion

●      Reduce glucagon release

 

Together, these mechanisms help reduce food intake, manage blood glucose, and increase satiety -a powerful combination for those struggling with obesity or type 2 diabetes.

Clinical Results: What Do the Studies Say?

Phase 2 Trials

Participants who took Orforglipron daily for 26–36 weeks experienced:

●      Weight loss of 8.6% to 14.7%

 

●      Significant improvement in long-term glucose control (HbA1c)

●      Better outcomes compared to placebo and other GLP-1 injections in early-stage studies

Phase 3 Trials (Ongoing)

Current large-scale trials suggest that those on 36mg daily lost up to 7.9% of their body weight after 40 weeks, alongside a 1.5% drop in HbA1c levels -comparable to established injectable medications.

Benefits of Orforglipron

•     Taken as a daily tablet – no injections needed
•       Effective appetite control
•       Supports weight loss in obese or overweight individuals
•       Improves blood sugar in type 2 diabetes
• Reduces risk of injection-related anxiety or discomfort

Its oral format makes it particularly appealing to those hesitant about using needles.

Orforglipron vs. Other GLP-1 Medications

Medication	Delivery	% Lost ≥10% Weight	Study Duration
Orforglipron (36mg)	Oral	75%	36 weeks
Semaglutide (2.4mg)	Injection	66.1%	68 weeks
Tirzepatide (15mg)	Injection	90.1%	72 weeks

Despite a shorter study duration, Orforglipron shows comparable outcomes — and with the added ease of oral dosing.

Possible Side Effects

As with other GLP-1 agonists, gastrointestinal side effects are the most common:

●      Nausea

●      Vomiting

●      Diarrhoea

●      Constipation

Most effects are mild and improve over time. Long-term safety continues to be assessed during phase 3 trials.

When Will Orforglipron Be Available in the UK?

Orforglipron UK is currently not licensed for use in the UK. The manufacturer, Eli Lilly, is expected to seek US approval for obesity treatment by late 2025, with a UK submission to NICE likely in 2026.

If approved, Orforglipron may be offered in the UK for weight loss and type 2 diabetes management by late 2026.

Final Thoughts: A Promising Step Forward

Orforglipron could reshape how we treat weight and blood sugar concerns -offering a needle-free alternative with strong clinical promise. If you struggle with weight loss, pre-diabetes, or type 2 diabetes, Orforglipron may be worth discussing with a specialist as it becomes available.

Stay Updated with MedCare Health Clinic

We specialise in GLP-1 treatments like Wegovy® and Mounjaro®, with prescription support and nationwide delivery. Check back regularly for updates on Orforglipron’s availability.

👉 Need help with weight loss treatment in Preston or online?
 Book a consultation with MedCare Health Clinic & Pharmacy

 

 

References

1. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity – The New England Journal of Medicine
    https://www.nejm.org/doi/full/10.1056/NEJMoa2309355
   Learn more about the Orforglipron oral GLP-1 weight loss tablet
2. Lilly’s Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results – Eli Lilly Press Release
    https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
3. Efficacy and Safety of Oral Orforglipron in Type 2 Diabetes – The Lancet
    https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00062-2/fulltext
4. Wiley Online Library – Orforglipron (LY3502970), a Novel GLP-1 Receptor Agonist
    https://onlinelibrary.wiley.com/doi/10.1002/dmrr.3728
   
5. Wegovy 0.25 mg, FlexTouch – Summary of Product Characteristics – Electronic Medicines Compendium (emc)
    https://www.medicines.org.uk/emc/product/13759/smpc